Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | Director · President, CEO, and Director | August 22, 2026 | August 25, 2026 |
| SenesTech, Inc.SNES · Entity 8221 | Director | June 15, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date August 22, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 418,908 |
Reported balance
After 2026-08-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-22 · Tax withholding · Disposed 1,451 · Balance 418,908 F1: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. F2: Included in this number are 142,836 unvested restricted stock units, 104,516 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027. |
| Common StockSEC Table I · non-derivative | IndirectFamily Holdings | 47,296 |
Reported balance
Holding disclosure · report date 2026-08-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 47,296 F3: Shares are held by the Gregg Family Grandchildren's Trust UAD 12/30/2010, with respect to which the Reporting Person's spouse is a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.
F2: Included in this number are 142,836 unvested restricted stock units, 104,516 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
F3: Shares are held by the Gregg Family Grandchildren's Trust UAD 12/30/2010, with respect to which the Reporting Person's spouse is a trustee.
SenesTech, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2036-06-15 | Direct | 100,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 100,000 · Balance 100,000 F1: Monthly over 1 year (12 equal monthly installments) |
Filing footnotes · ownership attribution and instrument terms
F1: Monthly over 1 year (12 equal monthly installments)
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2026 Filed Aug 25, 2026 20:14 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 1,451 | $92.34 | $133,985.34 |
DisclosureSEC source: 0001093557-26-000159 · wk-form4_1787688890.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · Director · President, CEO, and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 418,908 F1 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. F2 · balance_after: Included in this number are 142,836 unvested restricted stock units, 104,516 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:20 UTC | SenesTech, Inc. SNES · Entity 8221 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001628280-26-043913 · wk-form4_1781727643.xml · derivative · entry 1 Leach Jacob Steven · CIK 0001700255 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-06-15 F1 · derivative.exercise_date: Monthly over 1 year (12 equal monthly installments) Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:39 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 1,451 | $71.90 | $104,326.90 |
DisclosureSEC source: 0001093557-26-000099 · wk-form4_1779914354.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · Director · President, CEO, and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,359 F1 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. F2 · balance_after: Included in this number are 145,686 unvested restricted stock units, 104,516 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| March 08, 2026 Filed Mar 10, 2026 20:01 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 19,757 | $68.10 | $1,345,451.70 |
DisclosureSEC source: 0001093557-26-000046 · wk-form4_1773172894.xml · nonDerivative · entry 2 Leach Jacob Steven · CIK 0001700255 · Director · President, CEO, and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,810 F2 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. F3 · balance_after: Included in this number are 148,536 unvested RSUs, 104,516 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| March 08, 2026 Filed Mar 10, 2026 20:01 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 104,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-26-000046 · wk-form4_1773172894.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · Director · President, CEO, and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,567 F1 · shares: Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:46 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 3,058 | $73.36 | $224,334.88 |
DisclosureSEC source: 0001093557-26-000013 · wk-form4_1770068801.xml · nonDerivative · entry 2 Leach Jacob Steven · CIK 0001700255 · Director · President, CEO, and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,051 F2 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of PSUs and does not represent a sale by the Reporting Person. F3 · balance_after: Included in this number are 84,537 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 8,465 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 102 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:46 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 8,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-26-000013 · wk-form4_1770068801.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · Director · President, CEO, and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,109 F1 · shares: Represents shares issued to the Reporting Person upon vesting of performance-based restricted stock units (PSUs) granted to the Reporting Person on March 8, 2023, resulting from achievement of performance conditions under the PSUs. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 00:48 UTC | SenesTech, Inc. SNES · Entity 8221 | SaleCommon Stock | 62 | $2.71 | $168.02 |
DisclosureSEC source: 0001628280-25-053306 · wk-form4_1763599720.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · balance_after: The amount of securities reported has been adjusted to reflect the 1-for-20 reverse stock split on November 15, 2022; the one-for-twelve reverse stock split on November 14, 2023; and the one-for-ten reverse stock split on July 11, 2024. Read SEC document |
| November 10, 2025 Filed Nov 11, 2025 00:13 UTC | DEXCOM INC DXCM · Entity 3114 | PurchaseCommon Stock | 2,500 | $55.43 | $138,563.00 |
DisclosureSEC source: 0001093557-25-000284 · wk-form4_1762819985.xml · nonDerivative · entry 2 Leach Jacob Steven · CIK 0001700255 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,697 F2 · price: This transaction was executed in multiple trades at prices ranging from $55.34 to $55.55. The price above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 84,537 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 8,465 of which were granted on March 8, 2023 and shall vest through March 8, 2026. Read SEC document |
| November 10, 2025 Filed Nov 11, 2025 00:13 UTC | DEXCOM INC DXCM · Entity 3114 | PurchaseCommon Stock | 15,700 | $54.98 | $863,138.90 |
DisclosureSEC source: 0001093557-25-000284 · wk-form4_1762819985.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,197 F1 · price: This transaction was executed in multiple trades at prices ranging from $54.34 to $55.33. The price above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 14,076 | $70.38 | $990,670.29 |
DisclosureSEC source: 0001093557-25-000081 · wk-form4_1741987530.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,497 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 84,537 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 8,465 of which were granted on March 8, 2023 and shall vest through March 8, 2026. Read SEC document |
| March 08, 2025 Filed Mar 11, 2025 23:17 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 22,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000065 · wk-form4_1741735047.xml · nonDerivative · entry 2 Leach Jacob Steven · CIK 0001700255 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,573 F2 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting from the date of grant as follows: 1/2 shall vest on March 8, 2026, 1/8 shall vest on May 22, 2026, 1/8 shall vest on August 22, 2026, 1/8 shall vest on November 8, 2026, and the remaining balance shall vest on March 8, 2027. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F3 · balance_after: Included in this number are 84,537 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 8,465 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 225 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on February 28, 2025. Read SEC document |
| March 08, 2025 Filed Mar 11, 2025 23:17 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 35,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000065 · wk-form4_1741735047.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,775 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. Read SEC document |
| January 29, 2025 Filed Jan 30, 2025 23:44 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,634 | $86.91 | $228,932.00 |
DisclosureSEC source: 0001093557-25-000016 · wk-form4_1738280640.xml · nonDerivative · entry 2 Leach Jacob Steven · CIK 0001700255 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,644 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 51,972 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 16,931 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 8,988 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 23:44 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 7,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000016 · wk-form4_1738280640.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,278 F1 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025. F1 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025. F2 · balance_after: Included in this number are 51,972 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 16,931 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 8,988 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 21:15 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 744 | $76.87 | $57,191.28 |
DisclosureSEC source: 0001093557-24-000190 · wk-form4_1734470124.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,171 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 51,972 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 16,931 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 8,988 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 23:05 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 746 | $69.15 | $51,585.90 |
DisclosureSEC source: 0001093557-24-000167 · wk-form4_1726095894.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,915 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 53,432 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 16,931 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 8,988 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 1,460 of which were granted on December 15, 2021 and shall vest through December 15, 2024, and 84 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on August 30, 2024. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 21:14 UTC | SenesTech, Inc. SNES · Entity 8221 | GrantStock Option (right to buy) · Derivative | 23,894 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001628280-24-038710 · wk-form4_1724879634.xml · derivative · entry 1 Leach Jacob Steven · CIK 0001700255 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,894 Underlying: Common Stock · 23,894 shares Expires 2034-08-27 F1 · derivative.exercise_date: The option will vest and become exercisable as to 25% of the total shares on November 27, 2024, February 27, 2025, May 27, 2025 and August 27, 2025, with 100% of the options fully vested on the earlier of the first anniversary of the date of grant or the first annual meeting of stockholders of the Corporation after the date of grant (subject to the recipient's continued service to the Corporation through such vesting date). Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 22:38 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 745 | $115.05 | $85,712.85 |
DisclosureSEC source: 0001093557-24-000127 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,577 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 54,896 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 16,931 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 8,988 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,924 of which were granted on December 15, 2021 and shall vest through December 15, 2024 and 145 additional shares purchased pursuant to the DexCom, Inc. 2015 Employee Stock Purchase Plan. Read SEC document |
| April 08, 2024 Filed Apr 9, 2024 19:10 UTC | SenesTech, Inc. SNES · Entity 8221 | GrantStock Option (right to buy) · Derivative | 4,469 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001628280-24-015423 · wk-form4_1712689809.xml · derivative · entry 1 Leach Jacob Steven · CIK 0001700255 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,469 Underlying: Common Stock · 4,469 shares Expires 2029-04-08 F1 · derivative.exercise_date: Fully vested on June 30, 2024 (subject to the recipient's continued service to the Company through such vesting date). Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 7,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-24-000051 · edgardoc.xml · nonDerivative · entry 2 Leach Jacob Steven · CIK 0001700255 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,177 F3 · shares: The transaction represents a gift by the Reporting Person of 7,736 shares to a charitable donor advised fund. F2 · balance_after: Included in this number are 56,356 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 16,931 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 8,988 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,384 of which were granted on December 15, 2021 and shall vest through December 15, 2024. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 14,639 | $134.41 | $1,967,638.24 |
DisclosureSEC source: 0001093557-24-000051 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,913 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 56,356 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 16,931 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 8,988 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,384 of which were granted on December 15, 2021 and shall vest through December 15, 2024. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 22:31 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 26,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-24-000037 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,552 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 56,356 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 16,931 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 8,988 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,384 of which were granted on December 15, 2021 and shall vest through December 15, 2024. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 23:49 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,978 | $123.63 | $491,819.23 |
DisclosureSEC source: 0001093557-24-000011 · edgardoc.xml · nonDerivative · entry 2 Leach Jacob Steven · CIK 0001700255 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,499 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 58,781 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 5,848 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 23:49 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 9,697 | $0.00 | $9.70 |
DisclosureSEC source: 0001093557-24-000011 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,477 F1 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2021 that vested on January 12, 2024. F1 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2021 that vested on January 12, 2024. F2 · balance_after: Included in this number are 58,781 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 5,848 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 21:37 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,932 | $121.85 | $357,265.67 |
DisclosureSEC source: 0001093557-23-000255 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,780 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 58,781 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 5,848 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| June 26, 2023 Filed Jun 29, 2023 22:44 UTC | SenesTech, Inc. SNES · Entity 8221 | GrantStock Option (right to buy) · Derivative | 41,010 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001628280-23-023954 · wk-form4_1688078631.xml · derivative · entry 1 Leach Jacob Steven · CIK 0001700255 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,010 Underlying: Common Stock · 41,010 shares Expires 2028-06-26 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total shares on September 26, 2023, December 26, 2023, March 26, 2024 and June 26, 2024, with 100% of the options fully vested on the earlier of the first anniversary of the grant date or the first annual meeting of stockholders of the Company after the grant date (subject to the recipient's continued service to the Company through such vesting date). Read SEC document |
| April 20, 2023 Filed Apr 20, 2023 22:39 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 30,764 | $125.00 | $3,845,500.00 |
DisclosureSEC source: 0001093557-23-000110 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,613 F1 · shares: On December 5, 2022, Mr. Leach adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Leach. The shares set forth above were sold pursuant to the 10b5-1 Plan. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 64,633 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 4,583 | $111.40 | $510,541.62 |
DisclosureSEC source: 0001093557-23-000079 · edgardoc.xml · nonDerivative · entry 3 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,377 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 64,633 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 7,986 | $111.40 | $889,632.41 |
DisclosureSEC source: 0001093557-23-000079 · edgardoc.xml · nonDerivative · entry 2 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,960 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 64,633 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,540 | $111.40 | $394,352.46 |
DisclosureSEC source: 0001093557-23-000079 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,946 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 64,633 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 20:59 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 25,397 | $0.00 | $25.40 |
DisclosureSEC source: 0001093557-23-000054 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,486 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 64,633 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 01:05 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,719 | $115.13 | $888,706.22 |
DisclosureSEC source: 0001093557-23-000034 · edgardoc.xml · nonDerivative · entry 2 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,089 F1 · shares: On December 5, 2022, Mr. Leach adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Leach. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $114.79 to $115.64. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 73,448 unvested restricted stock units, 26,964 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 19,120 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 15,664 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 01:05 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 10,425 | $114.45 | $1,193,116.23 |
DisclosureSEC source: 0001093557-23-000034 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,808 F1 · shares: On December 5, 2022, Mr. Leach adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Leach. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $113.77 to $114.755. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 73,448 unvested restricted stock units, 26,964 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 19,120 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 15,664 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 22:14 UTC | SenesTech, Inc. SNES · Entity 8221 | GrantStock Option (right to buy) · Derivative | 199,071 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-041323 · doc4.xml · derivative · entry 1 Leach Jacob Steven · CIK 0001700255 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,071 Underlying: Common Stock · 199,071 shares Expires 2027-07-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total shares on the first day of each calendar quarter following the date of grant, with 100% of the options fully vested on the earlier of the first anniversary of the grant date or the first annual meeting of stockholders of the Company after the grant date (subject to the recipient's continued service to the Company through such vesting date).This option was issued to the reporting person pursuant to the Company's Non-Employee Director Compensation Program in lieu of retainer and meeting fees of $27,000. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:25 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 891 | $406.06 | $361,796.52 |
DisclosureSEC source: 0001093557-22-000049 · edgardoc.xml · nonDerivative · entry 4 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,746 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 18,362 unvested restricted stock units, 6,741 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 4,780 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:25 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,065 | $406.06 | $838,507.09 |
DisclosureSEC source: 0001093557-22-000049 · edgardoc.xml · nonDerivative · entry 3 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,637 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 18,362 unvested restricted stock units, 6,741 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 4,780 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:25 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 1,317 | $406.06 | $534,776.67 |
DisclosureSEC source: 0001093557-22-000049 · edgardoc.xml · nonDerivative · entry 2 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,702 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 18,362 unvested restricted stock units, 6,741 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 4,780 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 00:25 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 6,741 | $0.00 | $6.74 |
DisclosureSEC source: 0001093557-22-000049 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,019 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 18,362 unvested restricted stock units, 6,741 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 4,780 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 2,925 | $0.00 | $2.93 |
DisclosureSEC source: 0001093557-21-000292 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,247 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock. F2 · balance_after: Included in this number are 20,426 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,171 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 15 | $542.03 | $8,130.42 |
DisclosureSEC source: 0001093557-21-000214 · edgardoc.xml · nonDerivative · entry 2 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,322 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 17,501 unvested restricted stock units, 7,171 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,248 | $541.36 | $675,617.28 |
DisclosureSEC source: 0001093557-21-000214 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,337 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 17,501 unvested restricted stock units, 7,171 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| August 18, 2021 Filed Aug 18, 2021 23:49 UTC | SenesTech, Inc. SNES · Entity 8221 | PurchaseCommon Stock | 50,000 | $1.54 | $77,095.00 |
DisclosureSEC source: 0001225208-21-011565 · doc4.xml · nonDerivative · entry 3 Leach Jacob Steven · CIK 0001700255 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F3 · price: The price shown is a weighted average sales price. The shares were purchased at prices ranging from $1.49 to $1.55 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 23:49 UTC | SenesTech, Inc. SNES · Entity 8221 | PurchaseCommon Stock | 50,000 | $1.50 | $74,785.00 |
DisclosureSEC source: 0001225208-21-011565 · doc4.xml · nonDerivative · entry 2 Leach Jacob Steven · CIK 0001700255 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F2 · price: The price shown is a weighted average sales price. The shares were purchased at prices ranging from $1.48 to $1.52 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 23:49 UTC | SenesTech, Inc. SNES · Entity 8221 | PurchaseCommon Stock | 50,000 | $1.54 | $76,885.00 |
DisclosureSEC source: 0001225208-21-011565 · doc4.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price shown is a weighted average sales price. The shares were purchased at prices ranging from $1.52 to $1.54 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| July 30, 2021 Filed Aug 2, 2021 22:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 12,087 | $476.70 | $5,761,872.90 |
DisclosureSEC source: 0001093557-21-000193 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,554 F1 · shares: On March 5, 2021, the reporting person adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Leach. The sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 19,999 unvested restricted stock units, 7,171 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 22:32 UTC | SenesTech, Inc. SNES · Entity 8221 | GrantStock Option (right to buy) · Derivative | 33,762 | $0.95 Strike: $1.66 | $31,999.62 |
DisclosureSEC source: 0001225208-21-009710 · doc4.xml · derivative · entry 2 Leach Jacob Steven · CIK 0001700255 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,800 Underlying: Common Stock · 33,762 shares Expires 2026-06-25 F2 · price: This option was issued to the reporting person pursuant to the Company's Non-Employee Director Compensation Program in lieu of retainer and meeting fees of $32,000. F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total shares on the first day of each calendar quarter following the date of grant, with 100% of the options fully vested on earlier of the first anniversary of the grant date or the first annual meeting of stockholders of the Company after the grant date (subject to the recipient's continued service to the Company through such vesting date). Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 22:32 UTC | SenesTech, Inc. SNES · Entity 8221 | GrantStock Option (right to buy) · Derivative | 39,038 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001225208-21-009710 · doc4.xml · derivative · entry 1 Leach Jacob Steven · CIK 0001700255 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,038 Underlying: Common Stock · 39,038 shares Expires 2026-06-25 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total shares on the first day of each calendar quarter following the date of grant, with 100% of the options fully vested on earlier of the first anniversary of the grant date or the first annual meeting of stockholders of the Company after the grant date (subject to the recipient's continued service to the Company through such vesting date). Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 21:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 22,755 | $395.00 | $8,988,225.00 |
DisclosureSEC source: 0001093557-21-000167 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,641 F1 · shares: On March 5, 2021, the reporting person adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Leach. The sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 19,999 unvested restricted stock units, 7,171 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:38 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,353 | $362.92 | $1,942,694.70 |
DisclosureSEC source: 0001093557-21-000074 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,396 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 19,999 unvested restricted stock units, 7,171 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.